BMS to present new overall survival data for Opdivo as monotherapy and in combination with Yervoy at AACR 2016 Annual Meeting
New, pivotal Phase III overall survival data from CheckMate -141 for Opdivo in previously treated advanced squamous cell carcinoma of the head and neck, to be presented.
Bristol-Myers Squibb (BMS) has announced that new clinical research data for two of its Immuno-Oncology medicines — Opdivo (nivolumab) and Yervoy (ipilimumab) — will be presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans, LA, from 16–20 April.
Data to be presented for Opdivo, as a single-agent and in combination with Yervoy, illustrate the company’s commitment to expanding its Immuno-Oncology research portfolio to include additional tumour types and developing treatment options that have the potential to extend survival in hard-to-treat cancers in broad patient populations.
Jean Viallet, MD, Global Clinical Research Lead, Oncology, BMS, commented: “At this year’s AACR, we are excited to present, for the first time, overall survival data from the first pivotal Phase III trial of an Immuno-Oncology agent, Opdivo, in previously treated squamous cell carcinoma of the head and neck, a cancer that has had very few treatment advances over the past 10 years. These head and neck cancer data represent the fifth tumour type with overall survival data for Opdivo compared to a standard of care. We will also be presenting overall survival data from CheckMate -069, which was the first randomized trial to evaluate the Opdivo + Yervoy Regimen in the first-line setting for advanced melanoma, and has been a foundational study in building our scientific understanding of combining these two Immuno-Oncology agents to treat this form of cancer.”
Key data presentations include
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance